A Phase I Study Of OSI-774 (NSC #718781)-Based Multimodality Therapy For Inoperable Stage III Non Small Cell Lung Cancer
Phase of Trial: Phase I
Latest Information Update: 31 Jan 2013
At a glance
- Drugs Erlotinib (Primary) ; Carboplatin; Cisplatin; Docetaxel; Etoposide; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 31 Jan 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 29 Aug 2005 New trial record.